2021
DOI: 10.1016/j.ejpb.2020.12.005
|View full text |Cite
|
Sign up to set email alerts
|

Evolution of drug-eluting biomedical implants for sustained drug delivery

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
33
0
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 56 publications
(37 citation statements)
references
References 171 publications
0
33
0
1
Order By: Relevance
“…Polymer coatings on implants and other biomedical devices are frequently used as local drug delivery systems, which allows for in situ release in the immediate targeted tissue, optimizing the therapeutic effects. Medications can be released at controlled rates in the range of effective treatment levels, increasing their bioavailability [1]. In this sense, mathematical modeling of drug delivery and release predictability is useful in development and understanding of drug release mechanisms from controlled delivery systems.…”
Section: Introductionmentioning
confidence: 99%
“…Polymer coatings on implants and other biomedical devices are frequently used as local drug delivery systems, which allows for in situ release in the immediate targeted tissue, optimizing the therapeutic effects. Medications can be released at controlled rates in the range of effective treatment levels, increasing their bioavailability [1]. In this sense, mathematical modeling of drug delivery and release predictability is useful in development and understanding of drug release mechanisms from controlled delivery systems.…”
Section: Introductionmentioning
confidence: 99%
“…Mechanical reperfusion with stent implantation is a life-saving operation for patients with acute infarction. The first implants, bare metal stents, were highly effective but caused in-stent restenosis after 6–12 months [ 15 ]. This complication is defined by the organization of fibrin surrounding the stent followed by neointimal proliferation.…”
Section: Iddss and Fbr: Current Clinical Landscapementioning
confidence: 99%
“…Bishop reported the first clinical use of IDDS for hormonal therapy in women [ 13 , 14 ]. Then, a few more implantable drug formulations were briefly studied [ 15 ]. Technologically, the era of the modern IDDS started in 1960s [ 9 ], when Folkman and Long demonstrated the application of a capsular (reservoir-type) device comprising a silicone rubber “Silastic” together with a semipermeable membrane, which used as a carrier for prolonged drug delivery to the ventricular myocardium in dogs with modeled heart block [ 16 ].…”
Section: Introductionmentioning
confidence: 99%
See 2 more Smart Citations